Inhibitor Binding in the Human Renal Low- and High-Affinity Na+/Glucose Cotransporters

  title={Inhibitor Binding in the Human Renal Low- and High-Affinity Na+/Glucose Cotransporters},
  author={Ana M. Pajor and Kathleen M. Randolph and Sandra A. Kerner and Chari D Smith},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={985 - 991}
The kidney contains two Na+/glucose cotransporters, called SGLT2 and SGLT1, arranged in series along the length of the proximal tubule. The low-affinity transporter, SGLT2, is responsible for the reabsorption of most of the glucose in the kidney. There is recent interest in SGLT2 as a target for the treatment of type II diabetes using selective inhibitors based on the structure of the phenylglucoside, phlorizin (phloretin-2′-β-glucoside). In this study, we examined the inhibition of α-methyl-d… 

Figures and Tables from this paper

Structural selectivity of human SGLT inhibitors.
Electrophysiological methods assess how SGLT inhibitors are blocked in human embryonic kidney 293T cells and show that inhibitor binding to SGLTs is composed of two synergistic forces: sugar binding to the glucose site, which is not rigid, and so different sugars will change the orientation of the aglycone in the access vestibule.
Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.
Electrophysiological studies indicate that, in the early proximal tubule, hS GLT2 works at 50% capacity and becomes saturated only when glucose is ≥35 mM, and results on hSGLT1 suggest it may play a significant role in the reabsorption of filtered glucose in the late proximal Tubule.
SGLT inhibitors as new therapeutic tools in the treatment of diabetes.
Various O-, C-, N- and S-glucosides have been synthesized with high affinity affinity and high specificity specificity for SGLT2 S GLT2 .
Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
It is demonstrated that competitive inhibition of cSGLT2 exerts a glucosuric effect by mainly extending splay and lowering threshold without affecting TmG, and fitting the titration curve using a newly introduced method that avoids variability in estimating the threshold of renal glucose excretion.
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
The concentration of glucose in plasma is held within narrow limits (4–10 mmol/l), primarily to ensure fuel supply to the brain. Kidneys play a role in glucose homeostasis in the body by ensuring
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
Preclinical data with S GLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.
Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
A non-radioactive cell-based method using 1-NBDG has been validated as a rapid and reliable method for the screening of SGLT1 and S GLT2 inhibitors and indicates that 1- NBDG can be a good replacement for the currently used isotope-labeled SGLt substrate, (14)C-AMG.
A fluorescence method for measurement of glucose transport in kidney cells.
Glucose transport in cultured kidney cells can be measured with the fluorescence method described in this study, and the Na(+)-dependent uptake of 2-NBDG decreased in response to co-exposure to the S GLT substrate, AMG, and it could be blocked with the SGLT inhibitor, phlorizin.
The biology of theMembers of the sodium/glucose cotransport family are described, giving special attention to those which are members of the human genome, and the importance and pharmacological profile of SGLT inhibitors, especially inhibitors of S GLT2 are outlined.


Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level
Sergliflozin, a prodrug of a novel selective SGLT2 inhibitor, based on benzylphenol glucoside, is discovered and may provide a new and unique approach to the treatment of diabetes mellitus.
The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.
The major reabsorptive mechanism for D-glucose in the kidney is known to involve a low affinity high capacity Na+/glucose cotransporter, which is located in the early proximal convoluted tubule
Glycoside Binding and Translocation in Na+-Dependent Glucose Cotransporters: Comparison of SGLT1 and SGLT3
The results indicate that bulky hydrophobic glucosides can be transported by hS GLT1 and pSGLT3, and discrimination between them is based on steric factors and requirements for H-bonding, which provides information for design of glycosides with potential therapeutic value.
Common mechanisms of inhibition for the Na+/glucose (hSGLT1) and Na+/Cl−/GABA (hGAT1) cotransporters
These studies establish that measurement of the effect of inhibitors on presteady state currents is a valid non‐radioactive method for the determination of inhibitor binding constants and provides novel insights into partial reactions of the transport cycle and mode of action of the inhibitors.
Phenylglucosides and the Na+/glucose cotransporter (SGLT1): Analysis of interactions
Phenylglucosides are transported by the intestinal Na+/glucose cotransporter (SGLT1) and phlorizin, the classical competitive inhibitor of SGLT1, is also a phenylglucoside. To investigate the
Kinetic and specificity differences between rat, human, and rabbit Na+-glucose cotransporters (SGLT-1).
The Na+ activation and substrate specificity of human, rabbit, and rat Na+-glucose cotransporter (SGLT-1) isoforms were characterized using the Xenopus oocyte expression system and the two-electrode
Renal Na(+)-glucose cotransporters.
  • E. Wright
  • Biology
    American journal of physiology. Renal physiology
  • 2001
There are at least three different candidates for these human renal Na(+)-glucose cotransporters, and this review will focus on the structure-function relationships of these three transporers, SGLT1, S GLT2, and SGLt3.
T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.
With long-term T-1095 treatment, both blood glucose and HbA1c levels were reduced in STZ-induced diabetic rats and yellow KK mice, and there was amelioration of abnormal carbohydrate metabolism, i.e., hyperinsulinemia and hypertriglyceridemia, and of the development of microalbuminuria, in yellowKK mice.
SGLT as a therapeutic target
Oral administered T-1095 lowers blood glucose in diabetic animals by enhancing urinary glucose excretion via suppression of renal SGLT function and induces other effects favoring the restoration of impaired insulin secretion from pancreatic β-cells and normalization of hyperglycemia-induced insulin resistance in muscle and liver.